U.S., March 17 -- ClinicalTrials.gov registry received information related to the study (NCT07472933) titled 'Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies' on March 05.
Brief Summary: This study aims to observe the efficacy and safety of the combination of vebecotototo monoclonal antibody and putli monoclonal antibody in the treatment of EGFR-positive refractory biliary malignant tumors.
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Cancer of Biliary Duct
Intervention:
DRUG: Vibecotecotamab combined with Putilimab for EGFR-positive refractory biliary malignant tumors
This study is a single-arm, prospective, phase II clinical trial, aiming to enroll patients w...